Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival

Alessandro Buda, Andrea Alberto Lissoni, Irene Floriani, Elena Biagioli, Chiara Gerardi, Cristina Bonazzi, Stefania Chiari, Luca Locatelli, Tiziana Dell'anna, Mauro Signorelli, Costantino Mangioni, Rodolfo Milani

Research output: Contribution to journalArticle

Abstract

Objective Neoadjuvant chemotherapy (NACT) is a valid treatment option for women with locally advanced cervical cancer (LACC). This study aims to evaluate the impact of sociodemographic factors, clinical factors, and NACT regimens on survival endpoints. The role of pathological response to NACT as a surrogate endpoint of survival was also assessed. Materials and Methods Retrospective analysis of consecutive sample data from women with LACC (stages Ib2-IVa) who underwent NACT followed by radical surgery was performed. Response was classified as optimal response (including complete response and optimal partial response), suboptimal partial response, stable disease, and progressive disease. Results Four hundred forty-six women who had undergone surgery from 1992 to 2011 were analyzed. The overall optimal response was 35.4%. At a median follow-up of 12.7 years, 165 women (37.0%) experienced recurrence or died. Increase in patient age at surgery, International Federation of Gynecology and Obstetrics stage III/IV versus stage Ib2, and lymph-node positivity versus negativity seemed to impact negatively on survival, whereas neoadjuvant platinum-Taxol-containing regimens (compared with platinum-based regimens) improved survival. Response to NACT could be considered a surrogate endpoint of survival. Conclusions Age, International Federation of Gynecology and Obstetrics stage III/IV, lymph-node involvement, and type of NACT administered have a significant impact on survival. Response to NACT is a good surrogate endpoint of survival in patients with LACC.

Original languageEnglish
Pages (from-to)1468-1475
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume25
Issue number8
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Uterine Cervical Neoplasms
Biomarkers
Drug Therapy
Survival
Platinum
Gynecology
Obstetrics
Lymph Nodes
Paclitaxel
Recurrence

Keywords

  • Cervical cancer
  • Neoadjuvant chemotherapy
  • Optimal response
  • Radical surgery
  • Surrogate endpoint

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer : Validity of pathological response as surrogate endpoint of survival. / Buda, Alessandro; Lissoni, Andrea Alberto; Floriani, Irene; Biagioli, Elena; Gerardi, Chiara; Bonazzi, Cristina; Chiari, Stefania; Locatelli, Luca; Dell'anna, Tiziana; Signorelli, Mauro; Mangioni, Costantino; Milani, Rodolfo.

In: International Journal of Gynecological Cancer, Vol. 25, No. 8, 01.10.2015, p. 1468-1475.

Research output: Contribution to journalArticle

Buda, Alessandro ; Lissoni, Andrea Alberto ; Floriani, Irene ; Biagioli, Elena ; Gerardi, Chiara ; Bonazzi, Cristina ; Chiari, Stefania ; Locatelli, Luca ; Dell'anna, Tiziana ; Signorelli, Mauro ; Mangioni, Costantino ; Milani, Rodolfo. / Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer : Validity of pathological response as surrogate endpoint of survival. In: International Journal of Gynecological Cancer. 2015 ; Vol. 25, No. 8. pp. 1468-1475.
@article{a100ed143a594101aafa7356a9062886,
title = "Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival",
abstract = "Objective Neoadjuvant chemotherapy (NACT) is a valid treatment option for women with locally advanced cervical cancer (LACC). This study aims to evaluate the impact of sociodemographic factors, clinical factors, and NACT regimens on survival endpoints. The role of pathological response to NACT as a surrogate endpoint of survival was also assessed. Materials and Methods Retrospective analysis of consecutive sample data from women with LACC (stages Ib2-IVa) who underwent NACT followed by radical surgery was performed. Response was classified as optimal response (including complete response and optimal partial response), suboptimal partial response, stable disease, and progressive disease. Results Four hundred forty-six women who had undergone surgery from 1992 to 2011 were analyzed. The overall optimal response was 35.4{\%}. At a median follow-up of 12.7 years, 165 women (37.0{\%}) experienced recurrence or died. Increase in patient age at surgery, International Federation of Gynecology and Obstetrics stage III/IV versus stage Ib2, and lymph-node positivity versus negativity seemed to impact negatively on survival, whereas neoadjuvant platinum-Taxol-containing regimens (compared with platinum-based regimens) improved survival. Response to NACT could be considered a surrogate endpoint of survival. Conclusions Age, International Federation of Gynecology and Obstetrics stage III/IV, lymph-node involvement, and type of NACT administered have a significant impact on survival. Response to NACT is a good surrogate endpoint of survival in patients with LACC.",
keywords = "Cervical cancer, Neoadjuvant chemotherapy, Optimal response, Radical surgery, Surrogate endpoint",
author = "Alessandro Buda and Lissoni, {Andrea Alberto} and Irene Floriani and Elena Biagioli and Chiara Gerardi and Cristina Bonazzi and Stefania Chiari and Luca Locatelli and Tiziana Dell'anna and Mauro Signorelli and Costantino Mangioni and Rodolfo Milani",
year = "2015",
month = "10",
day = "1",
doi = "10.1097/IGC.0000000000000515",
language = "English",
volume = "25",
pages = "1468--1475",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer

T2 - Validity of pathological response as surrogate endpoint of survival

AU - Buda, Alessandro

AU - Lissoni, Andrea Alberto

AU - Floriani, Irene

AU - Biagioli, Elena

AU - Gerardi, Chiara

AU - Bonazzi, Cristina

AU - Chiari, Stefania

AU - Locatelli, Luca

AU - Dell'anna, Tiziana

AU - Signorelli, Mauro

AU - Mangioni, Costantino

AU - Milani, Rodolfo

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objective Neoadjuvant chemotherapy (NACT) is a valid treatment option for women with locally advanced cervical cancer (LACC). This study aims to evaluate the impact of sociodemographic factors, clinical factors, and NACT regimens on survival endpoints. The role of pathological response to NACT as a surrogate endpoint of survival was also assessed. Materials and Methods Retrospective analysis of consecutive sample data from women with LACC (stages Ib2-IVa) who underwent NACT followed by radical surgery was performed. Response was classified as optimal response (including complete response and optimal partial response), suboptimal partial response, stable disease, and progressive disease. Results Four hundred forty-six women who had undergone surgery from 1992 to 2011 were analyzed. The overall optimal response was 35.4%. At a median follow-up of 12.7 years, 165 women (37.0%) experienced recurrence or died. Increase in patient age at surgery, International Federation of Gynecology and Obstetrics stage III/IV versus stage Ib2, and lymph-node positivity versus negativity seemed to impact negatively on survival, whereas neoadjuvant platinum-Taxol-containing regimens (compared with platinum-based regimens) improved survival. Response to NACT could be considered a surrogate endpoint of survival. Conclusions Age, International Federation of Gynecology and Obstetrics stage III/IV, lymph-node involvement, and type of NACT administered have a significant impact on survival. Response to NACT is a good surrogate endpoint of survival in patients with LACC.

AB - Objective Neoadjuvant chemotherapy (NACT) is a valid treatment option for women with locally advanced cervical cancer (LACC). This study aims to evaluate the impact of sociodemographic factors, clinical factors, and NACT regimens on survival endpoints. The role of pathological response to NACT as a surrogate endpoint of survival was also assessed. Materials and Methods Retrospective analysis of consecutive sample data from women with LACC (stages Ib2-IVa) who underwent NACT followed by radical surgery was performed. Response was classified as optimal response (including complete response and optimal partial response), suboptimal partial response, stable disease, and progressive disease. Results Four hundred forty-six women who had undergone surgery from 1992 to 2011 were analyzed. The overall optimal response was 35.4%. At a median follow-up of 12.7 years, 165 women (37.0%) experienced recurrence or died. Increase in patient age at surgery, International Federation of Gynecology and Obstetrics stage III/IV versus stage Ib2, and lymph-node positivity versus negativity seemed to impact negatively on survival, whereas neoadjuvant platinum-Taxol-containing regimens (compared with platinum-based regimens) improved survival. Response to NACT could be considered a surrogate endpoint of survival. Conclusions Age, International Federation of Gynecology and Obstetrics stage III/IV, lymph-node involvement, and type of NACT administered have a significant impact on survival. Response to NACT is a good surrogate endpoint of survival in patients with LACC.

KW - Cervical cancer

KW - Neoadjuvant chemotherapy

KW - Optimal response

KW - Radical surgery

KW - Surrogate endpoint

UR - http://www.scopus.com/inward/record.url?scp=84943196369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943196369&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000515

DO - 10.1097/IGC.0000000000000515

M3 - Article

C2 - 26222484

AN - SCOPUS:84943196369

VL - 25

SP - 1468

EP - 1475

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 8

ER -